Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: In patients affected by heart failure (HF) with reduced ejection fraction (HFrEF), pharmacological treatments have been proven to alleviate symptoms and improve prognosis, while no treatment other than sodium-glucose co-transporter-2 inhibitors have demonstrated significant effects in HF with preserved ejection fraction (HFpEF). Left atrium decompression devices (LADd) have been recently investigated as a new interventional approach in patients with HFpEF.
Objectives: To assess the efficacy of LADd on soft endpoints in HF patients across the spectrum of ejection fraction.
Methods: PubMed and Web of Science were searched without restrictions from inception to 28 May 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed. The prespecified main outcomes were the change from baseline in 6-min walking distance (6MWD), NYHA class and health-related quality of life (HRQoL). Secondary outcomes were reduction in HF hospitalizations, echocardiographic, and hemodynamic parameters.
Results: Eleven studies, with a total of 547 patients, were included. LADd significantly improved 6MWD by 43.95 m (95% CI 29.64-58.26 m), decreased NYHA class by 0.93 (95% CI 1.20-0.67), and improved HRQoL questionnaire by 20.45 points (95% CI 13.77-27.14) with better results for all outcomes in patients with lower EFs.
Conclusion: The present meta-analysis suggests that LADd are favorable in improving 6MWD, NYHA class, and HRQoL in HF across a wide spectrum of ejection fraction, with better outcomes in patients with lower EFs.
Trial Registration: CRD42022336077, URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=336077 .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403397 | PMC |
| http://dx.doi.org/10.1007/s10741-023-10317-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical presentation and echocardiographic characteristics of women with peripartum cardiomyopathy: Insights from the Italian Multicentre Registry.
Int J Cardiol
September 2025
Federico II University, Naples, Italy; Federico II University Hospital, Naples, Italy. Electronic address:
Background: Peripartum cardiomyopathy (PPCM) is a rare, life-threatening form of heart failure occurring in late pregnancy or postpartum, with variable clinical course and outcomes. We report preliminary clinical and echocardiographic findings from a national Italian registry of PPCM patients METHODS: The study was approved by the institutional Ethics Committee and registered at ClinicalTrials.gov (NCT05878041).
View Article and Find Full Text PDFRationale and Design of the Comparative Effectiveness of ICD Versus Non-ICD Therapy in Contemporary Heart Failure Patients at a Low Risk for Arrhythmic Death (CONTEMP-ICD) trial.
Am Heart J
September 2025
Baylor Scott and White Research Institute and HealthCare, Dallas TX. Electronic address:
Background: Current recommendations for a prophylactic (primary prevention) implantable cardioverter defibrillator (ICD) in patients with both ischemic and non-ischemic heart failure with reduced ejection fraction (HFrEF) originate from clinical trials conducted in selected patients over 20 years ago that showed an overall statistically significant survival benefit associated with a primary prevention ICD in the range of 23%-34%. The recent introduction of angiotensin receptor-neprilysin inhibitors [ARNI] and sodium glucose co-transporter 2 inhibitors [SGLT2i]) was shown to further reduce the risk of sudden cardiac death (SCD) in patients with HFrEF. Thus, there is an unmet need appropriately designed comparative effectiveness clinical trials aimed to reassess the survival benefit of a primary prevention ICD in contemporary patients with HFrEF.
View Article and Find Full Text PDFArtificial intelligence in HFpEF: Diagnosis, prognosis, and management strategies.
J Cardiol
September 2025
Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Cardiology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic addr
Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of all HF cases and its incidence and prevalence continue to increase, with a substantial burden of morbidity and mortality. Despite advances in our understanding of heterogeneous pathophysiology underlying HFpEF, the diagnosis, risk assessment, and management of this disease entity remain challenging in everyday practice. Artificial intelligence (AI) algorithm can handle large amounts of complex data and machine learning (ML), a subfield of AI, allows for the identification of relevant patterns by learning from big data.
View Article and Find Full Text PDFThe Scottish inflammatory prognostic score: A novel biomarker for predicting in-hospital mortality in acute heart failure with reduced ejection fraction.
Heart Lung
September 2025
Department of Cardiology, School of Medicine, Mugla Sitki Kocman University, Mugla, Turkey. Electronic address:
Background: Acute heart failure with reduced ejection fraction (AHF) remains a leading cause of ED visits, hospitalizations, and in-hospital mortality.
Objectives: To evaluate the prognostic utility of the Scottish Inflammatory Prognostic Score (SIPS) in patients with AHF.
Methods: This retrospective study analyzed 508 patients admitted with AHF between November 2022 and November 2024.
Safety and Tolerability of Diuretic Withdrawal in Stable Euvolemic Patients With Heart Failure With Reduced Ejection Fraction.
JACC Heart Fail
September 2025
Department of Cardiology, Reina Sofia University Hospital, Cordoba, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba, Cordoba, Spain; CIBER de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.